US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rapport Therapeutics, Inc.

31.47

+17.11119.15%

Pre-market: 30.70-0.7700-2.45%07:08 EDT

Volume:13.88M

Turnover:482.52M

Market Cap:1.15B

PE:-12.56

High:42.27

Open:38.42

Low:27.05

Close:14.36

52wk High:42.27

52wk Low:6.43

Shares:36.50M

Float Shares:14.96M

Volume Ratio:41.34

T/O Rate:92.77%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.5062

EPS(LYR):-3.7760

ROE:-29.42%

ROA:-20.14%

PB:4.36

PE(LYR):-8.33

Loading ...

Overview Company News Filings

Rapport's Seizure Drug Hits in Phase 2, Sending Stock Soaring

Tiger Newspress

U.S. RESEARCH ROUNDUP- IQVIA Holdings, Reliance, United Therapeutics

Rapport Therapeutics Inc : Jonestrading Raises Target Price to $50 From $42

THOMSON REUTERS

BUZZ-Rapport Therapeutics ticks up after commencing $250 mln equity offering

BRIEF-Rapport Announces Proposed Public Offering Of Common Stock

Rapport Therapeutics Terminates Common Stock Prospectus

JonesTrading Sticks to Its Buy Rating for Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics Announces Planned $250 Million Share Offering

MT Newswires Live

Rapport Therapeutics announces $250M common stock offering

BRIEF-Rapport Therapeutics Terminates ATM Prospectus - SEC Filing

Rapport Therapeutics Inc. Announces $250 Million Public Offering of Common Stock

Rapport Announces Proposed Public Offering of Common Stock

THOMSON REUTERS

Rapport Therapeutics Inc - Announces $250 Mln Public Offering

THOMSON REUTERS

Rapport Therapeutics Inc - Terminates Atm Prospectus - SEC Filing

THOMSON REUTERS

Rapport Therapeutics Inc. Terminates ATM Prospectus for Common Stock Sales Agreement

Top Midday Gainers

MT Newswires Live

Rapport Therapeutics price target raised to $56 from $35 at Stifel

BUZZ-U.S. STOCKS ON THE MOVE-Sanofi SA, Nutanix, Bullish

Rapport Therapeutics Up Over 93%, on Pace for Record Percent Increase -- Data Talk

Rapport Shares Soar On Positive Anti-Seizure Treatment Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/RAPP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAPP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","market":"US","secType":"STK","nameCN":"Rapport Therapeutics, Inc.","latestPrice":31.47,"timestamp":1757361600000,"preClose":14.36,"halted":0,"volume":13877633,"hourTrading":{"tag":"盘前","latestPrice":30.7,"preClose":31.47,"latestTime":"07:08 EDT","volume":3418,"amount":105206.060508,"timestamp":1757416082151},"delay":0,"floatShares":14959986,"shares":36497920,"eps":-2.506155,"marketStatus":"Pre-Mkt","change":17.11,"latestTime":"09-09 07:09:21 EDT","open":38.42,"high":42.2685,"low":27.052,"amount":482515668.332698,"amplitude":1.059645,"askPrice":31.5,"askSize":4,"bidPrice":30.59,"bidSize":299,"shortable":3,"etf":0,"ttmEps":-2.506155,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1757424600000},"marketStatusCode":1,"adr":0,"listingDate":1717732800000,"exchange":"NASDAQ","adjPreClose":31.47,"preHourTrading":{"tag":"盘前","latestPrice":30.7,"preClose":31.47,"latestTime":"07:08 EDT","volume":3418,"amount":105206.060508,"timestamp":1757416082151},"postHourTrading":{"tag":"盘后","latestPrice":31.5,"preClose":31.47,"latestTime":"19:59 EDT","volume":155398,"amount":4591762.383,"timestamp":1757375999999},"volumeRatio":41.33601547831223,"impliedVol":1.0783,"impliedVolPercentile":0.6751},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","floatShares":14959986,"roa":"-20.14%","roe":"-29.42%","lyrEps":-3.775953,"volumeRatio":41.33601547831223,"shares":36497920,"dividePrice":0,"high":42.2685,"amplitude":1.059645,"preClose":14.36,"low":27.052,"week52Low":6.43,"pbRate":"4.36","week52High":42.2685,"institutionHeld":0,"latestPrice":31.47,"committee":0.973597,"eps":-2.506155,"divideRate":0,"volume":13877633,"delay":0,"ttmEps":-2.506155,"open":38.42,"prevYearClose":17.74,"prevWeekClose":14.36,"prevMonthClose":17.63,"prevQuarterClose":11.37,"fiveDayClose":17.63,"twentyDayClose":14.55,"sixtyDayClose":12.1},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAPP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-07","symbol":"RAPP","fiscalQuarterEnding":"2025/06","expectedEps":-0.87,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":-0.75},{"market":"US","date":"2025-05-08","symbol":"RAPP","fiscalQuarterEnding":"2025/03","expectedEps":-0.77,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-03-11","symbol":"RAPP","fiscalQuarterEnding":"2024/12","expectedEps":-0.62,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"pre","actualEps":-0.57},{"market":"US","date":"2024-11-07","symbol":"RAPP","fiscalQuarterEnding":"2024/09","expectedEps":-0.57,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.5}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAPP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RAPP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1754712000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RAPP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RAPP","date":"2025-09-05","current":-6.343907,"percent":0.661342,"low":-19.654107,"twenty":-13.171889,"median":-8.282979,"eighty":-5.126995,"high":-3.640031,"avg":-9.27442,"sd":4.171847,"marketCap":560243072},"quantilePoints":[{"date":"2024-06-07","current":-14.341434,"twenty":-13.293406,"median":-11.721364,"eighty":-11.721364,"marketCap":735830305},{"date":"2024-06-14","current":-17.322989,"twenty":-16.966549,"median":-15.024031,"eighty":-12.769392,"marketCap":888807905},{"date":"2024-06-21","current":-15.733266,"twenty":-17.881887,"median":-15.772475,"eighty":-14.348329,"marketCap":807242405},{"date":"2024-06-28","current":-16.581593,"twenty":-17.17471,"median":-16.18238,"eighty":-14.635158,"marketCap":850768389},{"date":"2024-07-05","current":-17.059223,"twenty":-17.829134,"median":-16.431888,"eighty":-15.672154,"marketCap":875274616},{"date":"2024-07-12","current":-18.299635,"twenty":-18.057796,"median":-16.595851,"eighty":-15.733266,"marketCap":938917651},{"date":"2024-07-19","current":-14.343149,"twenty":-18.092899,"median":-16.610109,"eighty":-15.733266,"marketCap":735918314},{"date":"2024-07-26","current":-16.431888,"twenty":-18.057796,"median":-16.50674,"eighty":-14.592658,"marketCap":843087333},{"date":"2024-08-02","current":-15.740395,"twenty":-18.021611,"median":-16.417631,"eighty":-14.614044,"marketCap":807608170},{"date":"2024-08-09","current":-11.062669,"twenty":-17.829134,"median":-16.189509,"eighty":-14.507112,"marketCap":697147270},{"date":"2024-08-16","current":-12.078391,"twenty":-17.822005,"median":-15.897228,"eighty":-14.341434,"marketCap":761156070},{"date":"2024-08-23","current":-12.943207,"twenty":-17.322989,"median":-15.776039,"eighty":-12.769083,"marketCap":815654991},{"date":"2024-08-30","current":-12.623979,"twenty":-17.301602,"median":-15.672154,"eighty":-12.252515,"marketCap":795537939},{"date":"2024-09-06","current":-11.799793,"twenty":-17.107699,"median":-14.956226,"eighty":-12.030797,"marketCap":743599370},{"date":"2024-09-13","current":-11.027844,"twenty":-17.007896,"median":-14.603351,"eighty":-11.813723,"marketCap":694952683},{"date":"2024-09-20","current":-12.322165,"twenty":-16.6871,"median":-14.421566,"eighty":-11.752199,"marketCap":776518182},{"date":"2024-09-27","current":-12.380206,"twenty":-16.587296,"median":-14.342291,"eighty":-11.752199,"marketCap":780175827},{"date":"2024-10-04","current":-12.072587,"twenty":-16.581593,"median":-13.041877,"eighty":-11.742318,"marketCap":760790305},{"date":"2024-10-11","current":-12.798103,"twenty":-16.461829,"median":-12.783593,"eighty":-11.721364,"marketCap":806510876},{"date":"2024-10-18","current":-15.061713,"twenty":-16.461829,"median":-13.041877,"eighty":-11.742318,"marketCap":949159059},{"date":"2024-10-25","current":-14.057599,"twenty":-16.431888,"median":-14.106934,"eighty":-11.752199,"marketCap":885881788},{"date":"2024-11-01","current":-14.289764,"twenty":-16.420482,"median":-14.289764,"eighty":-11.78122,"marketCap":900512371},{"date":"2024-11-08","current":-13.587752,"twenty":-16.360601,"median":-14.196898,"eighty":-11.792828,"marketCap":976225637},{"date":"2024-11-15","current":-10.665545,"twenty":-16.293733,"median":-13.709352,"eighty":-11.752199,"marketCap":766276774},{"date":"2024-11-22","current":-11.755009,"twenty":-16.213426,"median":-13.641207,"eighty":-11.719637,"marketCap":844550392},{"date":"2024-11-29","current":-11.627735,"twenty":-16.188083,"median":-13.405914,"eighty":-11.573511,"marketCap":835406277},{"date":"2024-12-06","current":-10.416089,"twenty":-16.139607,"median":-12.943207,"eighty":-11.450385,"marketCap":748354310},{"date":"2024-12-13","current":-9.555718,"twenty":-15.982774,"median":-12.73716,"eighty":-11.371152,"marketCap":686540097},{"date":"2024-12-20","current":-9.199351,"twenty":-15.858733,"median":-12.415031,"eighty":-11.254059,"marketCap":660936577},{"date":"2024-12-27","current":-9.688083,"twenty":-15.824515,"median":-12.350651,"eighty":-11.045256,"marketCap":696049976},{"date":"2025-01-03","current":-9.917175,"twenty":-15.797425,"median":-12.316361,"eighty":-10.975704,"marketCap":712509382},{"date":"2025-01-10","current":-7.539701,"twenty":-15.740395,"median":-12.304752,"eighty":-10.859002,"marketCap":541697328},{"date":"2025-01-17","current":-6.460419,"twenty":-15.733266,"median":-12.215086,"eighty":-10.644772,"marketCap":464155239},{"date":"2025-01-24","current":-7.076424,"twenty":-15.684376,"median":-12.087097,"eighty":-10.43238,"marketCap":508412752},{"date":"2025-01-31","current":-8.354253,"twenty":-15.597056,"median":-11.915876,"eighty":-10.137105,"marketCap":600219659},{"date":"2025-02-07","current":-8.211706,"twenty":-15.257893,"median":-11.843324,"eighty":-9.686047,"marketCap":589978251},{"date":"2025-02-14","current":-8.094614,"twenty":-15.103195,"median":-11.828814,"eighty":-9.441681,"marketCap":581565666},{"date":"2025-02-21","current":-6.455328,"twenty":-15.070846,"median":-11.799793,"eighty":-9.297098,"marketCap":463789474},{"date":"2025-02-28","current":-5.106225,"twenty":-15.037336,"median":-11.771597,"eighty":-9.077168,"marketCap":366861863},{"date":"2025-03-07","current":-4.373128,"twenty":-15.01412,"median":-11.747556,"eighty":-8.771711,"marketCap":314191765},{"date":"2025-03-14","current":-4.898381,"twenty":-14.977526,"median":-11.717047,"eighty":-8.416363,"marketCap":383577552},{"date":"2025-03-21","current":-4.530187,"twenty":-14.817535,"median":-11.627735,"eighty":-8.164869,"marketCap":354745367},{"date":"2025-03-28","current":-4.68399,"twenty":-14.676319,"median":-11.461087,"eighty":-7.790176,"marketCap":366789191},{"date":"2025-04-04","current":-4.189957,"twenty":-14.640334,"median":-11.410917,"eighty":-7.133443,"marketCap":328102968},{"date":"2025-04-11","current":-4.315796,"twenty":-14.632186,"median":-11.370643,"eighty":-6.989878,"marketCap":337957006},{"date":"2025-04-17","current":-4.730597,"twenty":-14.622599,"median":-11.327444,"eighty":-6.74653,"marketCap":370438835},{"date":"2025-04-25","current":-4.949801,"twenty":-14.60549,"median":-11.189913,"eighty":-6.457364,"marketCap":387604034},{"date":"2025-05-02","current":-5.280719,"twenty":-14.55844,"median":-11.048158,"eighty":-5.528775,"marketCap":413517298},{"date":"2025-05-09","current":-4.693792,"twenty":-14.472894,"median":-10.976093,"eighty":-5.332796,"marketCap":374099938},{"date":"2025-05-16","current":-4.560992,"twenty":-14.4176,"median":-10.940782,"eighty":-5.2164,"marketCap":363515647},{"date":"2025-05-23","current":-5.092192,"twenty":-14.397354,"median":-10.8247,"eighty":-5.097805,"marketCap":405852811},{"date":"2025-05-30","current":-3.896992,"twenty":-14.370288,"median":-10.665545,"eighty":-4.981023,"marketCap":310594193},{"date":"2025-06-06","current":-5.646289,"twenty":-14.346875,"median":-10.527934,"eighty":-4.950803,"marketCap":450014853},{"date":"2025-06-13","current":-5.101351,"twenty":-14.342806,"median":-10.416089,"eighty":-4.981023,"marketCap":406582762},{"date":"2025-06-20","current":-5.050978,"twenty":-14.341434,"median":-10.309179,"eighty":-5.014344,"marketCap":402568031},{"date":"2025-06-27","current":-5.408165,"twenty":-14.289764,"median":-9.866266,"eighty":-5.000606,"marketCap":431036124},{"date":"2025-07-03","current":-5.513507,"twenty":-14.247974,"median":-9.698265,"eighty":-5.011596,"marketCap":439432031},{"date":"2025-07-11","current":-7.043002,"twenty":-14.172521,"median":-9.586263,"eighty":-5.043651,"marketCap":561334272},{"date":"2025-07-18","current":-6.795718,"twenty":-14.077333,"median":-9.430989,"eighty":-5.078884,"marketCap":541625526},{"date":"2025-07-25","current":-7.610838,"twenty":-13.779001,"median":-9.362262,"eighty":-5.090926,"marketCap":606591391},{"date":"2025-08-01","current":-6.57591,"twenty":-13.6976,"median":-9.168805,"eighty":-5.092192,"marketCap":524106641},{"date":"2025-08-08","current":-6.368661,"twenty":-13.694662,"median":-9.054259,"eighty":-5.099519,"marketCap":562429202},{"date":"2025-08-15","current":-6.17446,"twenty":-13.609134,"median":-8.982986,"eighty":-5.10525,"marketCap":545278924},{"date":"2025-08-22","current":-6.170327,"twenty":-13.473486,"median":-8.4968,"eighty":-5.115317,"marketCap":544913945},{"date":"2025-08-29","current":-6.943168,"twenty":-13.38251,"median":-8.407708,"eighty":-5.122916,"marketCap":613165056},{"date":"2025-09-05","current":-6.343907,"twenty":-13.171889,"median":-8.282979,"eighty":-5.126995,"marketCap":560243072}],"updateTime":1757385953107},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAPP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1113665380","title":"Rapport's Seizure Drug Hits in Phase 2, Sending Stock Soaring","url":"https://stock-news.laohu8.com/highlight/detail?id=1113665380","media":"Tiger Newspress","labels":["movement"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1113665380?lang=en_us&edition=fundamental","pubTime":"2025-09-08 22:06","pubTimestamp":1757340370,"startTime":"0","endTime":"0","summary":"A phase 2a trial of $Rapport Therapeutics(RAPP)$’ focal onset seizure drug candidate has hit its primary endpoint, sending shares in the biotech up more than 170% in morning trading.The study...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Rapport's Seizure Drug Hits in Phase 2, Sending Stock Soaring","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP"],"gpt_icon":0},{"id":"2566664517","title":"U.S. RESEARCH ROUNDUP- IQVIA Holdings, Reliance, United Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2566664517","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566664517?lang=en_us&edition=fundamental","pubTime":"2025-09-09 15:29","pubTimestamp":1757402941,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- IQVIA Holdings, Reliance, United TherapeuticsSept 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nL3N3UW0GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0098860793.USD","MEDP","LU0047713382.USD","CEG","SGXZ51526630.SGD","UTHR","LU1791807156.HKD","TASK","SRPT","BAC","LU1861220207.SGD","PIPR","CRL","ELF","INSM","WING","LU0081259029.USD","LU0823434583.USD","LU2458330169.SGD","BK4108","CMG","IE00B0169N27.USD","BK4606","RS","BK4121","TKO","RAPP","BK4614","LU1720051017.SGD","SEE","FTRE","BK4179","APEI","NGS","BMI","LU2360106780.USD","LU0320765992.SGD","EPAM","BK4127","FDS","LU0390134368.USD","SATS","IQV","HSY","IE00B19Z3B42.SGD","BK4204","LU1242518857.USD","EMN"],"gpt_icon":1},{"id":"2566668857","title":"Rapport Therapeutics Inc : Jonestrading Raises Target Price to $50 From $42","url":"https://stock-news.laohu8.com/highlight/detail?id=2566668857","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566668857?lang=en_us&edition=fundamental","pubTime":"2025-09-09 12:17","pubTimestamp":1757391471,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nFWN3UW00J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2566563779","title":"BUZZ-Rapport Therapeutics ticks up after commencing $250 mln equity offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2566563779","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566563779?lang=en_us&edition=fundamental","pubTime":"2025-09-09 05:25","pubTimestamp":1757366718,"startTime":"0","endTime":"0","summary":"extended trading as co looks to raise equity after its stock soared. ** RAPP shares on Mon closed up ~119% at $31.47 after its seizure drug, RAP-219, met mid-stage trial goals. ** After the bell, co commences $250 mln stock offering. ** It intends to use net proceeds to primarily fund ongoing and planned clinical trials advancing RAP-219, other R&D and for working capital and other purposes, per the prospectus filing. ** Goldman Sachs, Jefferies, TD Cowen and Stifel are joint bookrunners. ** Boston-headquartered Rapport has ~36.5 mln shares outstanding for ~$1.1 bln current market cap. ** Rapport, backed by Johnson & Johnson JNJ.N, went public in Jun 2024 after IPO priced at $17. ** All 6 analysts are bullish on RAPP; median PT of $50 up from $35 a month ago, per LSEG data","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nL6N3UV11R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0004086264.USD","LU0795875169.SGD","IE00B7SZLL34.SGD","LU0122379950.USD","LU0882574055.USD","BK4588","LU1066053197.SGD","LU1506573853.SGD","LU2237443465.HKD","IE00BVYPNW00.USD","SF","IE00BGHQF631.EUR","LU2471134879.HKD","LU1668664300.SGD","LU2237443382.USD","LU0345770308.USD","LU1430594728.SGD","LU0203345920.USD","LU1267930813.SGD","LU1674673691.USD","IE0002270589.USD","IE00B3PB1722.GBP","LU2237443549.SGD","LU0742534661.SGD","LU1868837300.USD","LU2750360641.GBP","IE00BDGV0183.EUR","IE00BN8TJ469.HKD","LU2468319806.SGD","LU2237438978.USD","LU2265009873.SGD","LU0320765646.SGD","LU1221951046.USD","IE0034235303.USD","LU1674673428.USD","BK4552","IE00B19Z3B42.SGD","JNJ","LU2430703251.USD","LU0795875086.SGD","LU1585245621.USD","LU1868836757.USD","RAPP","LU1066051498.USD","IE0004091025.USD","LU2430703178.SGD","LU2471134952.CNY","BK4007","IE00B3T34201.USD","LU1032466523.USD"],"gpt_icon":0},{"id":"2566882637","title":"BRIEF-Rapport Announces Proposed Public Offering Of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2566882637","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566882637?lang=en_us&edition=fundamental","pubTime":"2025-09-09 04:47","pubTimestamp":1757364458,"startTime":"0","endTime":"0","summary":"BRIEF-Rapport Announces Proposed Public Offering Of Common StockSept 8 (Reuters) - Rapport Therapeutics Inc RAPP.O:RAPPORT ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCKRAPPORT THERAPEUTICS INC - ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nTUA5C1BNW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2566327636","title":"Rapport Therapeutics Terminates Common Stock Prospectus","url":"https://stock-news.laohu8.com/highlight/detail?id=2566327636","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566327636?lang=en_us&edition=fundamental","pubTime":"2025-09-09 04:39","pubTimestamp":1757363981,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc. ( ($RAPP) ) has shared an announcement. On September 8, 2025, Rapport Therapeutics, Inc. terminated its sales agreement ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-terminates-common-stock-prospectus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-terminates-common-stock-prospectus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","RAPP","BK4139","BK4007"],"gpt_icon":0},{"id":"2566632273","title":"JonesTrading Sticks to Its Buy Rating for Rapport Therapeutics, Inc. (RAPP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2566632273","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566632273?lang=en_us&edition=fundamental","pubTime":"2025-09-09 04:35","pubTimestamp":1757363704,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Justin Walsh reiterated a Buy rating on Rapport Therapeutics, Inc. today and set a price target of $50.00. The company’s share...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-its-buy-rating-for-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-its-buy-rating-for-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP"],"gpt_icon":0},{"id":"2566632539","title":"Rapport Therapeutics Announces Planned $250 Million Share Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2566632539","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566632539?lang=en_us&edition=fundamental","pubTime":"2025-09-09 04:22","pubTimestamp":1757362964,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics (RAPP) said Monday it started an underwritten public offering of $250 million of shares, subject to market conditions.Underwriters will be given a 30-day option to buy up to an ad","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4007","LENZ","RAPP","BK4139"],"gpt_icon":0},{"id":"2566632394","title":"Rapport Therapeutics announces $250M common stock offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2566632394","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566632394?lang=en_us&edition=fundamental","pubTime":"2025-09-09 04:10","pubTimestamp":1757362253,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics (RAPP) announced that it has commenced an underwritten public offering of $250M of shares of its common stock. Goldman Sachs &...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-announces-250m-common-stock-offering-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-announces-250m-common-stock-offering-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0742534661.SGD","LU0251131958.USD","LU2471134879.HKD","BK4585","IE00BFXG1179.USD","LU0048573561.USD","LU1894683348.USD","LU2471134952.CNY","LU2237443549.SGD","LU1868836914.USD","IE0002270589.USD","LU2750360997.AUD","LU0096364046.USD","LU0061475181.USD","LU1868836757.USD","LU1868837136.USD","LU1894683264.USD","LU1791807156.HKD","RAPP","LU1668664300.SGD","IE0004086264.USD","BK4533","LU1868837300.USD","LU0106831901.USD","LU2265009873.SGD","LENZ","IE0034235188.USD","LU2750360641.GBP","BK4539","LU0251142724.SGD","LU2237443622.USD","BK4550","LU2237443895.HKD","BK4504","LU2237443978.SGD","IE00BSNM7G36.USD","BK4139","BK4007","IE00B19Z3B42.SGD","IE0004091025.USD","LU1868836591.USD","BK4588","LU1804176565.USD","BK4127","LU2237443465.HKD","LU2471134796.USD","BK4516","LU2237443382.USD","LU2237438978.USD","BK4552"],"gpt_icon":0},{"id":"2566634788","title":"BRIEF-Rapport Therapeutics Terminates ATM Prospectus - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2566634788","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566634788?lang=en_us&edition=fundamental","pubTime":"2025-09-09 04:09","pubTimestamp":1757362152,"startTime":"0","endTime":"0","summary":"BRIEF-Rapport Therapeutics Terminates ATM Prospectus - SEC FilingSept 8 (Reuters) - Rapport Therapeutics Inc RAPP.O:RAPPORT THERAPEUTICS INC - TERMINATES ATM PROSPECTUS - SEC FILINGSource text: [ID:n0001193125-25-198322]Further company coverage: RAPP.O ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nFWN3UV1EL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2566634265","title":"Rapport Therapeutics Inc. Announces $250 Million Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2566634265","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566634265?lang=en_us&edition=fundamental","pubTime":"2025-09-09 04:05","pubTimestamp":1757361936,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Inc., a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders, has announced a public offering of $250 million in common stock. The offering, which is subject to market and other conditions, will be underwritten by Goldman Sachs & Co. LLC, Jefferies, TD Cowen, and Stifel, acting as joint book-running managers. Rapport also plans to grant underwriters a 30-day option to purchase an additional $37.5 million in shares at the public offering price, excluding underwriting discounts and commissions. The offering will be conducted under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL7mt2X3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0096364046.USD","LU2237443622.USD","LU1868836757.USD","LU2237443549.SGD","LU0061475181.USD","IE00BSNM7G36.USD","LU1791807156.HKD","LU2210150020.SGD","LU1894683264.USD","BK4112","LU1804176565.USD","LU2750360997.AUD","IE00B64PRP62.GBP","LU2237443895.HKD","IE0004091025.USD","LU1868837136.USD","LU2471134879.HKD","RAPP","LU1668664300.SGD","LU0251142724.SGD","IE00B19Z3581.USD","LU0048573561.USD","LU1868836591.USD","LU2750360641.GBP","LU0251131958.USD","BK4588","IE0004086264.USD","LU2210149790.SGD","LU2237443382.USD","BK4504","IE00B19Z3B42.SGD","LU0742534661.SGD","IE0034235188.USD","LU2095319765.USD","IE00BFXG1179.USD","LU1868837300.USD","LU0106831901.USD","LU1868836914.USD","BK4127","LU2237438978.USD","LU2471134796.USD","BK4585","NDAQ","BK4552","BK4516","LU2471134523.USD","IE00BGHQF748.EUR","LU2237443465.HKD","LU0314104364.USD","BK4550"],"gpt_icon":0},{"id":"2566963448","title":"Rapport Announces Proposed Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2566963448","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566963448?lang=en_us&edition=fundamental","pubTime":"2025-09-09 04:05","pubTimestamp":1757361900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nTUA5C1BNW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2566634406","title":"Rapport Therapeutics Inc - Announces $250 Mln Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2566634406","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566634406?lang=en_us&edition=fundamental","pubTime":"2025-09-09 04:05","pubTimestamp":1757361900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nTUA5C1BNW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2566363446","title":"Rapport Therapeutics Inc - Terminates Atm Prospectus - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2566363446","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566363446?lang=en_us&edition=fundamental","pubTime":"2025-09-09 04:03","pubTimestamp":1757361826,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nFWN3UV1EL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2566634488","title":"Rapport Therapeutics Inc. Terminates ATM Prospectus for Common Stock Sales Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2566634488","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566634488?lang=en_us&edition=fundamental","pubTime":"2025-09-09 04:03","pubTimestamp":1757361792,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Inc. has announced the termination of its sales agreement prospectus, which was filed under the company's registration statement on Form S-3. Effective September 8, 2025, the decision halts any sales of the company's common stock under the existing Sales Agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. Unless a new prospectus, prospectus supplement, or registration statement is filed, no shares will be issued or sold. Despite this termination, the Sales Agreement itself remains active, and as of the effective date, no shares had been issued or sold under it.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDG","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDLc029fj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNSH","RAPP"],"gpt_icon":0},{"id":"2566636969","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2566636969","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566636969?lang=en_us&edition=fundamental","pubTime":"2025-09-09 01:47","pubTimestamp":1757353631,"startTime":"0","endTime":"0","summary":"Eightco Holdings  said Monday it priced a private placement for 171.2 million shares at $1.46 each for gross proceeds of about $250 million. The company also said it received a $20 million investment from BitMine Immersion Technologies .Shares soared multifold as intraday trading volume surged to over 181.6 million from a daily average of about 1.13 million.Rapport Therapeutics  said Monday its phase 2a clinical trial of RAP-219 in patients with drug-resistant focal onset seizures met its primary endpoint.Shares more than doubled as intraday trading volume soared to over 12.2 million from a daily average of roughly 179,000.Beyond Air  said Monday that the US Food and Drug Administration has granted orphan drug designation for its lead investigational therapy BA-101 to treat glioblastoma, which is an aggressive type of brain cancer.Shares surged over 59% as intraday trading volume soared to more than 157.2 million from a daily average of about 278,000.Price: 63.08, Change: +61.63, Perce","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4082","BMNR","RAPP","BK4007","BK4136","BK4147","XAIR","BK4023","OCTO"],"gpt_icon":0},{"id":"2566296633","title":"Rapport Therapeutics price target raised to $56 from $35 at Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2566296633","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566296633?lang=en_us&edition=fundamental","pubTime":"2025-09-09 00:00","pubTimestamp":1757347251,"startTime":"0","endTime":"0","summary":"Stifel raised the firm’s price target on Rapport Therapeutics (RAPP) to $56 from $35 and keeps a Buy rating on the shares after the company reporte...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-price-target-raised-to-56-from-35-at-stifel-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-price-target-raised-to-56-from-35-at-stifel-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","RAPP","SF"],"gpt_icon":0},{"id":"2566963367","title":"BUZZ-U.S. STOCKS ON THE MOVE-Sanofi SA, Nutanix, Bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2566963367","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566963367?lang=en_us&edition=fundamental","pubTime":"2025-09-08 23:53","pubTimestamp":1757346833,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Sanofi SA, Nutanix, BullishEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nL6N3UV0QZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","KRKR","002383","TMUS","LVWR","LU0320765646.SGD","LU1366333091.USD","DQ","LU0058720904.USD","SOS","EPAM","LU0724618433.USD","LU1934455194.USD","CNF","KDP","IPDN","PL","T","ECL","VZ","GEV","WIX","LU2065171402.SGD","LU1852331112.SGD","DNTH","PLSE","NFE","IDYA","IE00BVYPNV92.GBP","LU0225283273.USD","VEEV","ALB","BK4198","NCLH","LU2420271590.USD","BLSH","CMCSA","SOLV","LU0321505868.SGD","LU1978683503.SGD","SATS","KGS","NEM","LU0738911758.USD","NTNX","SBAC","LDI"],"gpt_icon":1},{"id":"2565463898","title":"Rapport Therapeutics Up Over 93%, on Pace for Record Percent Increase -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2565463898","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565463898?lang=en_us&edition=fundamental","pubTime":"2025-09-08 23:28","pubTimestamp":1757345280,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc.  is currently at $27.81, up $13.45 or 93.66%. --Would be highest close since Oct. 17, 2024, when it closed at $28.05. --Up 41.45% from 52 weeks ago , when it closed at $19.66. --Down 4.86% from its 52-week closing high of $29.23 on Oct. 16, 2024. --Up 288.95% from its 52-week closing low of $7.15 on March 3, 2025. --Traded as high as $42.27; new all-time intraday high . --Up 194.35% at today's intraday high; largest intraday percent increase on record ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","BK4139","LENZ","RAPP"],"gpt_icon":0},{"id":"2565898986","title":"Rapport Shares Soar On Positive Anti-Seizure Treatment Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2565898986","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565898986?lang=en_us&edition=fundamental","pubTime":"2025-09-08 20:01","pubTimestamp":1757332860,"startTime":"0","endTime":"0","summary":"Shares of Rapport Therapeutics surged after the company said a trial of its seizure treatment met its primary endpoint.The stock more than doubled in premarket trading to $35.20.The Boston company on Monday said its treatment was well tolerated in the 30-patient phase 2a trial and resulted in a statistically significant reduction in long episodes--the trial's primary endpoint--in patients with drug-resistant focal onset seizures. Rapport also said it recorded a 78% reduction in clinical seizures.The company said it plans to hold a meeting with the Food and Drug Administration in the fourth quarter and to begin pivotal trials in the third quarter of next year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"3d0049e0f4a19299524cf344ccce2b4c","theme_name":"🔥TrendingNo.26 · Rapport Therapeutics Phase 2a Trial Success for Seizure Drug Candidate","theme_type":2,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Rapport Shares Soar On Positive Anti-Seizure Treatment Results","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":51,"code":"91000000","status":"200"}]}}